
Alzheimer’s drug failure sends Lundbeck’s shares crashing
pharmafile | September 23, 2016 | News story | Medical Communications, Research and Development | Alzheimer's, Lundbeck, cultural failings
Lundbeck’s experimental idalopirdine has failed to meet its primary endpoint in its first Phase III trial in the treatment of Alzheimer’s.
The company saw its shares fall by 17% as a result of the news, its biggest drop in four years. The study could not reproduce the promising findings of earlier studies, with the drug failing to improve symptoms of the disease according to the Alzheimer’s Disease Assessment Scale-cognitive (ADAS-cog).
Idalopirdine promotes a chemical the brain uses to process thought by blocking a cell receptor called 5-HT6. The Copenhagen-based company has two additional late-stage studies ongoing, with results expected early next year.
Matt Fellows
Related Content

Lilly’s drug for early Alzheimer’s shows promising results
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …

Eli Lilly’s Kisunla approved by FDA for Alzheimer’s treatment
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Kisunla …

FDA accepts Eisai’s Leqembi sBLA for early AD treatment
Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted …






